- Investing.com
Clinical Breakthrough | Benitec's BB-301 gene therapy for OPMD achieved a remarkable 100% response rate in low-dose trials, positioning the company for potential FDA approval with promising efficacy signals. |
Regulatory Edge | Discover how Fast Track and Orphan Drug designations from FDA and EMA provide Benitec strategic advantages, potentially accelerating the path to market for its innovative OPMD treatment. |
Financial Outlook | With a $30 million capital raise and analyst price targets averaging $20.50, Benitec demonstrates investor confidence despite broader negative sentiment in the gene therapy sector. |
Technological Advantage | Explore Benitec's proprietary ddRNAi "silence and replace" platform, offering localized gene therapy that targets affected tissues directly while minimizing systemic exposure and side effects. |
Metrics to compare | BNTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.4x | −1.5x | −0.4x | |
PEG Ratio | −0.98 | −0.04 | 0.00 | |
Price/Book | 2.4x | 3.4x | 2.6x | |
Price / LTM Sales | - | 129.6x | 3.1x | |
Upside (Analyst Target) | 95.1% | 136.2% | 48.3% | |
Fair Value Upside | Unlock | 12.1% | 6.2% | Unlock |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.